Citigroup Maintains Buy on Allogene Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and raises the price target from $7 to $8.
August 09, 2024 | 10:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow maintains a Buy rating on Allogene Therapeutics and raises the price target from $7 to $8.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact investor sentiment and drive short-term price appreciation for Allogene Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100